Some biotech startups drop funding news like a sleepy pulse ox, flat, clinical, and barely twitching. Not Plexision. This one hits with the precision of a crossmatch and the timing of a six-hour rejection panel.
$365,000 may not sound like Series A swagger to the untrained eye, but this isn’t your average bio-buzzword baby. This is real science, real patients, and real impact. The Richard King Mellon Foundation knows the difference and just made a strategic investment in Plexision’s game-changing diagnostics.
Founded by two brothers who could walk into a transplant OR or a boardroom and still leave the room smarter: CEO Rajeev Sindhi, a 20-year diagnostics operator who runs Sandor Group like a playbook written in logistics code, and Dr. Rakesh Sindhi, MD, pediatric transplant surgeon, professor of surgery at the University of Pittsburgh, and co-architect of one of the most battle-tested cell-based assays the FDA’s ever seen.
Let’s talk platform. Plexision’s proprietary suite, Pleximmune™, PlexAPR™, PlexABMR™, PlexCMV™, and more, isn’t guessing. It’s measuring live-cell immune response and ranking transplant risks with machine learning. These aren’t “maybe” diagnostics. These are six-to-24-hour readouts that give clinicians exactly what they need to know, before rejection, before infection, before everything goes sideways.
Their Pleximmune™ test is FDA-approved. Their reference labs are CLIA-certified and CAP-accredited. Their trial data? Try 81% PPV and 75% NPV on antibody-mediated kidney rejection. That’s not theoretical. That’s real-world precision for the 40,000+ U.S. transplants every year, and counting.
And while most labs are still mailing PDFs, Plexision is building EHR-integrated APIs and prepping a multiplex AI dashboard for 2025. They’ve already launched a second lab in Hyderabad, India to scale the tech globally. You want addressable market? Try $2B in U.S. transplant diagnostics and a rapidly rising 12K+ annual transplants in India alone.
This latest infusion fuels AI / ML upgrades, automated lab workflows, and a commercial team targeting adult kidney, liver, and heart centers. More importantly, it proves you don’t need nine-figure noise to build a precision powerhouse. You need grit, patents, and founders who know that in medicine, timing is everything.
